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Summary 
The smaller form of the GABA-synthesizing enzyme glutamic acid decarboxylase (GADrs) is 
a major autoantigen in two human diseases that affect its principal sites of expression. Thus, 
destruction of pancreatic B cells, which results in insulin-dependent  diabetes mellitus (IDDM), 
and impairment of GABA-ergic synaptic transmission in Stiff-Man syndrome (SMS) are both 
characterized by circulating autoantibodies to GADrs. Anti-GADrs autoantibodies in IDDM are 
predominantly directed to conformational epitopes. Here we report the characterization of humoral 
autoimmune responses to GAD6s in 35 SMS patients, of whom 13 (37%) also had IDDM. All 
SMS patients immunoprecipitated native GAD6s and the main titers were orders of magnitude 
higher than in IDDM patients. Furthermore, in contrast to the situation in IDDM, autoantibodies 
in 35 of 35 (100%) of SMS patients recognized denatured GADrs on Western blots. Two major 
patterns  of epitope specificity were identified on Western blots.  The first pattern, detected in 
25 of 35 SMS patients (71%), of whom 11 had IDDM (44%), was predominantly reactive with 
a linear NH2-terminal  epitope residing in the first eight amino acids of GADrs.  Nine of nine 
individuals who were HLA-haplotyped in this group carried an IDDM susceptibility haplotype 
and HLA-DR3, DQw2 was particularly  abundant.  The second pattern, detected in 10 of 35 
patients  (29%) of whom two had IDDM (20%), included reactivity with the NH2-terminal 
epitope plus strong reactivity with one or more additional epitope(s) residing COOH-terminal 
to amino acid 101. The second epitope pattern may represent epitope spreading in the GAD6s 
molecule, but may also include some cases of epitope recognition associated with IDDM resistant 
HLA-haplotypes.  The  principal  NH2-terminal  linear  epitope  in  GADrs  distinguishes  the 
reactivity of SMS and IDDM autoantibodies  and may be a determinant of pathogenicity for 
GABA-ergic neurons.  The greater magnitude and distinct specificity of the humoral response 
to GAD6s in SMS may reflect a biased involvement of the T  helper cell type 2 (Th2) subset 
of CD4 + T cells and antibody responses, whereas IDDM is likely mediated by the Thl subset 
of CD4 + T  cells and cytotoxic T  cell responses. 
T 
he synthesizing enzyme for the inhibitory neurotrans- 
mitter GABA, glutamic acid decarboxylase (GAD)  1, is 
encoded by two nonallelic genes, GAD6s and GAD67 (1), 
which share a similar exon-intron structure and are probably 
t Abbreviations used in this patx,  r: AET, aminoethylisothiouranium  bromide; 
DTT, dithiothreitol; F/M, female/male;  GAD, glutamic acid decarboxylase; 
derived from a common ancestral gene (2). These two GAD 
proteins share extensive  homology  except in their first 95 amino 
HMAP, Hepes/NaOH/MgC12,  AET, PLP; ICA, islet cell cytoplasmic 
antibodies; IDDM, insulin-dependent diabetes mellitus; JDF; Juvenile 
Diabetes Foundation; PLP, pyridoxal 5'phosphate; PVDF, polyvinylidene 
difluoride; SMS, Stiff-Man syndrome; TBS, tfis-buffered saline. 
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cules (3), but only GAD6s, which is found in neurons and 
pancreatic/3 cells, undergoes posttranslational lipid modifica- 
tion in the  NH2-terminal  domain  to become targeted and 
anchored  to  the  membrane  of synaptic-like  microvesicles, 
which  store and secrete GABA (3-5). 
Autoantibodies to GAD6s are detected in ~80%  of indi- 
viduals  who  develop  insulin-dependent  diabetes  mellitus 
(IDDM)  (6,  7).  Autoantibodies  to GADs7 are detected in 
only a small fraction of IDDM patients, and seem to repre- 
sent  anti-GAD6s  autoantibodies  that  crossreact  with  the 
larger isoform (8, 9).  T  lymphocytes are implicated as the 
effectors of B cell destruction  (10).  GAD6s has been iden- 
tified as the primary T cell autoantigen in the nonobese dia- 
betic mouse model of IDDM, and induction of tolerance to 
GAD6s in young mice prevents the disease (11, 12). 
Autoantibodies to GAD65 are also found in a rare neuro- 
logical disorder called Stiff-Man syndrome (SMS) (13). Stiffness 
of axial muscles and superimposed painful spasms are charac- 
teristic of this disorder and are alleviated by beuzodiazepines, 
a finding  that  is consistent with  the hypothesis that  SMS 
represents an impairment of GABA-ergic neurotransmission 
in the central nervous system (14).  SMS is characterized by 
a 30-40%  coincidence with IDDM.  Conversely, however, 
SMS is diagnosed in ~1/104 IDDM patients and in ~1/106 
individuals in the general population.  If GAD is a primary 
autoantigen in both SMS and IDDM,  the question is why 
the diseases do not always coincide. At least three possibili- 
ties can be suggested. First, neurons and/3 cells may express 
forms of GAD that differ antigenicaUy.  Second, the accessi- 
bility of GAD to the immune system may differ in the two 
tissues because neurons, but not/3 cells, are protected by the 
blood brain barrier.  Third,  the humoral and/or cellular im- 
mune responses to GADrs may differ in  the two diseases. 
The demonstration that/3 cell and neuronal forms of GAD 
are identical with regard to antigenicity and sequence (3, 15-17) 
seems to exclude the first possibility, although minor differ- 
ences in posttranslational  modification have not been ruled 
out. The two tissues clearly do differ in their vulnerability 
to immune system interactions.  In addition to their seques- 
tration behind the blood brain barrier,  neurons do not ex- 
press MHC class I antigens (18). In contrast,/3 cells are readily 
accessible to circulating immunological effectors and express 
MHC class I antigens (19) that can target them for killing 
by cytotoxic T  lymphocytes (20, 21). These differences can 
explain why SMS is a rare disease in individuals afflicted with 
IDDM, but not why only 30-40% of SMS patients develop 
diabetes. To explain the low penetrance of IDDM in SMS, 
we hypothesize that  the immune mechanisms  in SMS and 
IDDM reflect distinct  recognition  of GAD. 
To assess possible differences in recognition of GAD, we 
have begun to characterize the target epitopes of the humoral 
autoimmune response in the two diseases. The predominant 
epitopes for GAD6s autoantibodies  associated with  IDDM 
are conformational and localized to the COOH-terminal and 
middle regions  of the  GAD6s molecule (22).  In rare cases 
where  IDDM  autoantibodies  recognize  the  denatured 
GAD6s molecule  on  Western  blots,  the  epitope has  been 
localized to the COOH-terminal domain and may represent 
the phenomenon of restricted epitope spreading (22, 23). We 
and others have shown that GAD autoantibodies in SMS react 
with the denatured antigen on Western blots (7, 13, 24) sug- 
gesting that  the humoral  autoimmune response to GAD6s 
differs in IDDM and SMS. In the present study we have charac- 
terized an epitope that clearly distinguishes  SMS autoanti- 
bodies from those of IDDM. 
Materials  and  Methods 
Antisera.  Sera  were obtained with informed consent from 33 
SMS patients identified at the Mayo Clinic (Rochester, MN) during 
the period of 1989-1992, and from two patients who attended the 
University of California, San Francisco (UCSF) Neurology Clinic 
during the period of 1991-1993. The patients were diagnosed using 
uniform  standardized criteria developed at the Mayo Clinic and 
adapted at UCSF (14). The age, sex, age at onset of SMS, and the 
coexistence with other autoimmune  disorders, including IDDM, 
are shown in Table 1. Control human sera included: (a) Sera from 
11 newly diagnosed IDDM patients. This group included a serum 
(no. 675, "IDDM serum 2" in this study, female aged 11 years) 
that is used as a standard for quantitative  analyses of GADrs au- 
toantibodies by several laboratories (9, 25, 26) and has an arbitrary 
value of 10 in our GADrs antibody assay (26). The remaining sera 
in this group were from 10 individuals selected  for having the highest 
GAD~s antibody reactivity amongst 143 newly diagnosed IDDM 
patients collected from the USA and Scandinavia (Table 2). (b) Sera 
from 10 healthy controls (female/male IF/M]  =  3:7; mean age _+ 
SD  =  29.8  _+ 4.1; range 22-34).  (c) Sera from 10 patients diag- 
nosed at UCSF with polyendocrine autoimmune disorder but not 
SMS (F/M  =  9:1; mean age •  SD = 45.7  •  19.5; range 31-75). 
Each autoimmtme disorder coexisting in the SMS patients was rep- 
resented in at least one of these control patients. Eight of the poly- 
endocrine control patients  had IDDM (duration  0-31  yr; mean 
_+ SD 12.6 _+  12.1) and six of those were GADrs antibody posi- 
tive (Table 2). 
Rabbit antisera 1267 and 1701 were raised against a 19-amino 
acid peptide  derived from  the COOH terminus  of rat GAD67. 
Both  sera react  equally weU with  rat  and  human  GAD65 and 
GAD67 (3, 27). Rabbit antiserum  2001 was raised against a pep- 
tide  corresponding  to  residues 83-93  of human  GAD6s. The 
mouse monoclonal antibody GAD6 (28) is specific for GAD6s (3, 
27) and was kindly donated by Dr. D. Gottlieb (Washington Univer- 
sity, St. Louis, MO). The mouse hybridoma GAD1 (29) was ob- 
tained from the American Type Culture Collection (Rockville, MD). 
Immunoprecipitation Analyses.  GAD~s  autoantibodies were ana- 
lyzed by a quantitative immunoprecipitation  assay using [3SS]me- 
thionine  labeled rat GAD65 transiently expressed in COS-7 cells 
as described in detail elsewhere (26). Human sera were analyzed 
at dilutions  of 1:10, 1:100, 1:1000, 1:10,000, and 1:100,000, and 
resulting immune complexes were isohted on protein A-Sepharose 
(Pharmacia LKB, Piscataway, NJ) and analyzed by SDS-PAGE. 
Seropositivity was scored on the basis of a visible GADrs signal 
obtained by analyses using a model 425 Phosphor-Imager (Molec- 
ular Dynamics, Inc., Sunnyvale, CA). Thus, each immunoprecipi- 
tare was quantitated  by phosphorimaging  with IDDM serum 2 
(no. 675) serving as a positive standard.  GADrs antibody values 
were calculated using the formula:  10  x  [(value for the GAD~s 
immunoprecipitate band in an unknown serum subtracted by value 
for background  area of identical size)/(value for IDDM serum 2 
subtracted by value for background  area of identical size)]. This 
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SMS  Age at 
Patient  serum  SMS age 
No.  Sex  sampling  at onset 
IDDM/age 
at onset  ICA 
Other auto- 
antibodies/ 
disorders 
GAD6sAb 
IMP titer 
1"  F  45  34  no* 
2  F  48  43  no  s 
3  F  40  36  noS 
4  F  41  39  no 
5  F  51  48  49 
6  F  35  34  34s 
7  F  34  26  noS 
8  M  40  27  no 
9  M  40  36  noS 
10  M  64  56  noS 
11  F  34  29  no 
12  F  43  40  no 
13  M  57  <47  no 
14  F  38  34  33s 
15  F  59  50  57 
16"  F  44  42  no 
17  P  36  32  16 
18  F  39  37  35 
19  F  54  44  noS 
20*  M  36  35  no 
21  M  63  59  63 
22  F  65  64  55s 
23  F  56  <52  Pre-DM 
52 
24  M  68  61  Pre-DM 
60 
25  F  39  39  No 
26  M  49  47  Pre-DM 
49 
27  F  50  N/A  no 
28  F  40  39  no 
29  M  50  47  no 
30  F  50  39  39 
31  M  70  67  70 
32*  F  47  43  no 
33  F  45  37  no 
34*  F  50  46  no 
35  F  60  48  no 
JDF units 
8,620 
819 
3,940 
8,620 
819 
8,620 
1,610 
1,800 
>10,000 
171 
1,800 
8,620 
1,087 
554 
2,660 
7,570 
253 
3,940 
345 
>20,000 
1,800 
374 
>10,000 
Neg. 
1,210 
115 
3,110 
2,370 
2,370 
>I0,000 
5,110 
>10,000 
>10,000 
>10,000 
5,110 
yes 
yes 
yes 
yes 
yes 
yes 
N/A 
yes 
N/A 
N/A 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
N/A 
yes 
N/A 
yes 
yes 
yes 
yes 
yes 
None 
yes 
N/A 
N/A 
yes 
yes 
yes 
yes 
N/A 
N/A 
5,260 
495 
10,150 
13,310 
2,920 
5,440 
7,040 
930 
16,620 
578 
3,460 
11,140 
1,166 
1,260 
2,870 
3,380 
444 
2,920 
4,100 
65,700 
1,654 
1,551 
10,660 
44 
3,450 
173 
6,090 
2,600 
1,338 
9,720 
1,561 
20,280 
9,500 
1,561 
752 
* African Americans, the remaining patients are caucasian. 
* Father had NIDDM. 
$ IDDM in first degree relative(s). N/A, information not available. 
IMP, immunoprecipitation. 
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Sex  Age  Age  GAD6sAb  IMP titer  GAD6sAb  IMP titer 
n  F/M  mean  _+  SD  range  median  range 
tMt  35  25/10  48  _+  10.1  34-70  2920  44-65,700 
IDDM  10"  2/8  4.6  _+  5.0  0.9-15  20.3  14.7-36.6 
PE  6*  5/1  48  _+  19  11-75  8.2  1.3-15.9 
* Selected for having the highest GAD6s antibody titer amongst 143 newly diagnosed IDDM patients, 115 (80%) of whom were positive for GAD6sAb 
with a median titer of 1.7. 
t From a group of 10 PE patients, 6 of whom were GADrsAb positive. 
IMP, immunoprecipitation. 
assay was used in the first GAD antibody workshop (Orlando, FL, 
April 1993) and yielded 100% sensitivity and 100% specificity. 
Expression Systems and Protein Synthesis.  The  generation  of 
recombinant baculovimses harboring either rat GAD6s (4), human 
GAD65, or human GAD67 (22) was  described earlier.  A recom- 
binant baculovirus for expressing an NHz-terminal deletion mu- 
tant of rat GAD6s lacking the first 101 amino acids was generated 
by first making a 2-kb deletion mutant by oligonucleotide-directed 
mutagenesis  (5),  cloning  this  mutant  into  the  EcoRI  site  of 
pBhescript (Stratagene,  La Jolla, CA), from which it was released 
by tmaI and NotI digestions, and finally inserting the mutant cDNA 
into the SmaI and NotI sites of the baculovirus expression vector 
pVL1393 (Invitrogen, San Diego, CA). A clone containing the sense 
orientation for the A1-101 mutant of rat GAD6s was used in a cal- 
cium phosphate cotransfection with wild-type Autographa califor- 
nica nuclear polyhedrosis virus. Recombinant viruses were isolated 
as described (30). Recombinant proteins were expressed from the 
baculovirus constructs in Sf9 cells. Generation of NHz-terminal 
deletions of a rat GAD6s mutant in which cysteines at positions 
30 and 45 have been substituted with alanines,  and insertion of 
the mutants  into  the  COt-cell expression vector pSV-SPORT 
(GIBCO BILL, Gaithersburg, MD) were described earlier (5). De- 
letion mutants lacking the first NHz-terminal 8 (A1-8),  15 (A1- 
15), and 23 (A1-23) amino acids of rat GADr5, respectively, were 
produced by transient transfection of COS-7 cells using lipofecta- 
mine (GIBCO BRL). 
For  Western  blot  analyses,  Sf9  or  COS-7  cells  expressing 
GAD6s, GAD67, or  NHz-terminal  deletion  mutants  of GAD6s 
were washed twice in cell harvest buffer (10 mM Hepes/NaOH, 
pH 7.4, 150 mM NaC1, 10 mM benzamidine/HC1,  0.1 mM PMSF), 
and lysed in HMAP buffer (10 mM Hepes/NaOH, pH 7.4, 1 mM 
MgC12, 1 mM aminoethylisothiouranium bromide hydrobromide 
[AET], 0.2 mM pyridoxal 5'phosphate [PLP]) containing 1% Triton 
X-114, and 0.1 mM PMSF at 4~  After centrifugation at 264,000 
g, 4~  for 30 min, the superuatant was collected and prepared 
for SDS-PAGE by boiling for 3 min in SDS sample buffer at a final 
concentration of 8 mM Tris/HC1,  15%  sucrose,  2%  SDS,  5% 
B-mercaptoethanol, and 0.006% bromophenol blue. 
A 58-kD tryptic fragment containing the COOH terminus was 
generated from rat or human GAD6s produced in Sf9 cells. Ap- 
proximately 60  x  106 Sf9 cells were harvested 72 h  after infec- 
tion with the appropriate baculovirus.  The cell pellet was extracted 
in 4 ml of HMAP buffer supplemented with 1% Triton X-114 and 
0.1 mM PMSF for 1 h on ice. The lysate was diluted with 21.6 
ml of HEMAP (HMAP supplemented with 1 mM EGTA) and 
treated with 5.4 ml of N-tosyl-t-phenylalanine-chloromethylketone 
(TPCK)-treated trypsin (2 mg/ml; Sigma Chemical Co., St. Louis, 
MO) for 20 min at 0~  The reaction was quenched by adding 
400/~1 of 100 mM PMSF and 6.8 ml 5 x  SDt-sample buffer. This 
material was used for Western blot analysis. 
The approximate location of the tryptic cleavage site was esti- 
mated based on the relative molecular weight of the fragment ob- 
tained by SDS-PAGE,  followed by sequencing of the NH2 ter- 
minus of the isolated peptide. Approximately 300  x  106 Sf9 cells 
infected for production of human GADrs were harvested and sus- 
pended in HMAP buffer containing 1% Triton X-114 and 0.1 mM 
PMSF,  and  incubated  for  1  h  on  ice.  The  cells  were  then 
homogenized using a Tissumizer homogenizer (Tekmar Co., Cin- 
cinnati, OH) for 30 s on ice. The cell lysate was centrifuged at 
100,000 g and the supernatant was applied to a phenyl-Sepharose 
CD4B column (Pharmacia  LKB) preeqnilibrated in buffer A (50 
mM potassium phosphate, pH 7.0, 10 mM dithiothreitol [DTT], 
1 mM AET, 0.2 mM PLP) containing 2 M  ammonium sulfate, 
then washed with 5 column volumes of buffer A containing 2 M 
ammonium sulfate. The protein was eluted using buffer A and a 
gradient with initially 0%  Triton X-100 and 1.5 M ammonium 
sulfate, and finally 2% Triton X-100 and 0 mM ammonium sul- 
fate. Fractions containing GAD activity were pooled and subjected 
to immunoat~nity chromatography using the GAD1 monoclonal 
antibody as described (27) except that the gel matrix was washed 
sequentially  with 10 volumes of buffer B (10 mM Hepes/NaOH, 
pH 7.4, 10 mM DTT, 1 mM AET, 0.2 mM PLP), 10 volumes of 
buffer B with 0.5 M NaC1 and 10 volumes of buffer B before elu- 
tion of GAD6s in 1-ml aliquots of buffer A at pH 11 and neutral- 
ized in 100 pl 1M potassium phosphate pH 6.5, 0.2 mM PLP. Pro- 
tein concentrations were determined using Coomassie Plus protein 
reagent (Pierce, Rockford, IL), using BSA as a standard.  Purified 
human GAD6s (81 #g/ml,  100 #1) was treated with 5 #1 of 0.2 
mg/ml TPCK-treated trypsin (1 #g in 5/zl) for 1 h at 0~  The 
reaction was  quenched by adding  10 #1 of 100 mM PMSF  and 
freezing at  -20~  The sample (13 pmol of the 58-kD protein) 
was subjected  to preparative SDS-PAGE and blotted to Pro Blott 
polyvinylidene difluoride (PVDF) membrane (Applied Biosystems, 
Inc., Foster City, CA). A slice of PVDF paper containing the 58 
kD fragment was used for gas phase sequencing using a gas phase 
sequencer (model 470A; Applied Biosystems, Inc.). The phenylthio- 
hydantoin (trrH)-derivatives were identified by reverse-phase HPLC 
using an on-line PTH analyzer (model 120A; Applied Biosystems, 
Inc.).  Electrophoresis,  blotting, and sequencing were carried out 
at the Biomedical Resource Center, UCSF. The results were con- 
sistent with the generation of two fragments by cleavage at either 
position 69 (lys) or 70 (arg). 
Western Blot Analyses.  To compare serum IgG specificities for 
GAD67, GAD65, the 58-kD fragment of GAD6s, and deletion mu- 
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tein on the gel. A preparation of full-length rat or human GAD6s 
was chosen as an arbitrary standard and titrated on Western blots. 
Each protein preparation was titrated and calibrated against this 
standard to obtain an identical signal on Western blots immuno- 
stained with rabbit 1267 antiserum, which is equally reactive  with 
both  GAD67 and  GAD6s (27). Finally, the  concentrations  of 
different proteins which consistently gave a signal equivalent to 
that of the GAD6s standard were tested several times on the same 
blots, to ensure equivalent signal intensities. Equal amounts of  full- 
length GAD67, GAD6s, 58-kD trypsin fragment of GAD6s, or de- 
letions mutants  of GAD6s were then  subjected to SDS-PAGE, 
blotted to Immobilon PVDF transfer membrane (Millipore Corp., 
Bedford, MA) and analyzed for binding of human IgG and animal 
antiserum IgG after dilution of sera as described earlier (27). In 
some experiments, human sera were preabsorbed using a homoge- 
nate of  noninfected  SD cells as indicated.  Sf9 cells  were homogenized 
in HMAP buffer (107 cells/ml) using a Tissumizer homogenizer 
(Tekmar Co.) for 1 rain on ice. The homogenate was centrifuged 
at 264,000g. Sera were incubated with 0.2 vol of Sf9 cell superna- 
tant for 16 h at 4~  diluted, and used for immunostaining of 
Western blots (27). 
Synthesis of  Peptides  for Blocking Studies.  Peptides  of 20 residues, 
spanning amino acids 1-119 of the human GAD6s molecule (17), 
and each overlapping the next sequence by 9 amino adds, were 
synthesized by a multiple peptide synthesizer (Advanced Chem- 
tech, Louisville,  KY), using fluorenylmethoxycarbonyl  (FMOC)- 
protected amino acids and amino acid resins (Bachem California, 
Torrance, CA). Side  chain deprotection and cleavage  from the resin 
were performed with trifluoroacetic acid/anisole/dimethylsulfide 
(9:0.5:0.5 vol/vol), and the Peptides were extracted  with ether. Pep- 
tide identity was confirmed by protein sequence analysis with a 
Protein Sequencer (Applied Biosystems,  Inc.). For blocking studies, 
the peptides were solubilized in TBS/Tween-20 buffer (20 mM 
Tris/HC1, pH 7.4, 150 mM NaC1, and 0.1% Tween-20) to a con- 
centration of  0.5 mg/ml. All Peptides, except  no. 8, dissolved  readily 
in this buffer. Because  peptide 8 (residues 78-97) was only partially 
soluble, it was used as a saturated solution which effectively  blocked 
the binding of rabbit antiserum 2001 (reactive  with residues 83-93 
in human GAD6s). 
Dot Blot Analyses.  Human GAD6s was extracted from SD cells 
and isolated to ~95% purity by immunoafl~nity  chromatography 
as described previously (27). Purified GAD6s at a concentration of 
55/~g/ml in 100 mM potassium phosphate, 0.2 mM PLP, 1 mM 
AET, 0.1% SDS, was boiled for 3 rain before spotting (0,2 #g) 
on Immobilon PVDF transfer membrane (Millipore Corp.) using 
a BILL  HybriDot Manifold (GIBCO BILL).  The PVDF membrane 
was blocked with TBS/Tween-20  buffer containing 3% milk pro- 
tein for 1 h at room temperature. The membranes were incubated 
with sera (diluted in TBS/Tween-20 buffer containing 2% BSA) 
for 1.5 h at room temperature; after three washes of 5 rain in 
TBS/Tween-20, they were incubated with alkaline phosphatase- 
conjugated goat anti-human IgG (Zymed  Laboratories, Inc., South 
San Francisco, CA) or anti-rabbit IgG (Zymed Laboratories, Inc.) 
at a dilution of 1:500 in 3% milk/TBS/Tween-20 buffer for 1 h 
at room temperature. After two washes of 5 rain in TBS/Tween- 
20 and one in TBS buffer, the blots were developed by incubation 
for 3 rain in 0.4 mM 5-bromo-4-chloro-3-indolyl phosphate and 
0.4 mM nitro blue tetrazolium in 150 mM Tris-HC1, pH 9.5, 100 
mM NaC1, and 5 mM MgC12. 
Human sera (SMS, IDDM, polyendocrine,  and normal sera) were 
diluted 1:100, 1:200, and 1:500 in TBS/Tween-20 buffer, 2% BSA. 
Rabbit antisera 1701 and 2001 were diluted in the same buffer, 
1:200,000 and 1:2,000, respectively. For Peptide blocking experi- 
ments, diluted sera were incubated overnight at 4~  with either 
a mixture of Peptides (0.3/~g/#l each), an individual peptide (0.3 
#g/~l), human GAD6s (5.5/~g/ml),  or no additive, before incu- 
bation with dot blots of purified human GAD6s. 
Analyses of lslet Cell Cytoplasmic Antibodies (ICA).  ICAs were 
analyzed  by indirect immunofluorescence  using frozen sections of 
human pancreas from blood group O-positive donors of cadaveric 
kidneys (31). Serum samples were titrated and end point titers were 
defined as the highest dilution of  detectable ICA-staining. Positive 
samples were expressed in Juvenile  Diabetes Foundation 0DF) units 
by comparing their end point dilution to a standard  calibration  curve 
using the international JDF reference serum provided by the Im- 
munology of Diabetes Workshops. This assay has performed in 
category A in the ICA proficiency  program conducted under the 
auspices of the Immunology of Diabetes Workshops (32). 
HLA-typing.  DRB1, DQB1, and DQA1 typing was performed 
with a PCR dot blot technique as described (33, 34). 
Results 
SMS  Sera Contain Higher Levels of Immunoprecipitating 
GAD6s Autoantibodies than IDDM Sera.  Sera from 35 SMS 
patients were analyzed for GAD6s autoantibodies by immu- 
noprecipitation of [3SS]methionine-labded  Triton X-114 de- 
tergent phase extracts of COS-7 cells expressing rat GAD6s 
(Table  1).  Anti-GAD6s  IgG  titers,  quantified  in  serially 
diluted sera by phosphorimager analyses, were orders of mag- 
nitude higher in SMS sera (Tables 1 and 2) than in IDDM 
sera and sera from patients with polyendocrine autoimmune 
disorder (Table 2).  Thus,  the GAD6s binding capacity of 
SMS IgG is orders of magnitude higher than that of IDDM 
IgG. Titers of ICA in the SMS patients were also higher (Table 
1, median titer 2660 JDF units) than in 327  ICA-positive 
newly onset IDDM sera analyzed by the same assay (median 
titer 110JDF units) (31). The correlation coefficient between 
ICA and GAD6s autoantibody titers in the 35 SMS patients 
was 0,77. 
SMS Epitopes Recognized in Denatured GAD6s, Are Absent 
in GAD67, and Distinct from IDDM Epitopes.  The 35 SMS 
sera were analyzed by immunoblotting for reactivity with 
equal amounts of denatured GAD6s and GAD67. Additional 
sera were tested from 11 IDDM patients, 10 healthy individ- 
uals, and 10 patients with polyendocrine autoimmune dis- 
order without SMS. No serum IgG bound to human or rat 
GAD67 on Western blots (Fig.  1 A, lanes 3, 5,  7,  9,  1I). 
IgG in all SMS sera reacted specifically with GAD65 (Fig.  1 
A, lanes 4, 6, 8), but no reactivity was found in the sera from 
patients with IDDM (Fig.  2,  lanes 22 and 25), polyendo- 
crine autoimmunity (Fig. 1, lane I0), or healthy control sub- 
jects (Fig.  1, lane 12; Fig. 2,  lanes 28 and 3I)  at the same 
dilution. To analyze whether the lack of reactivity of IDDM 
sera with GAD6s on Western blots was due to low titers 
rather than differences in epitope recognition, the IDDM sera 
used in this study were also analyzed at lower dilutions to 
obtain a final GAD6s antibody titer of 4 and compared with 
SMS sera analyzed at the same  titer.  To avoid nonspecific 
binding of SD cell proteins at high IgG concentrations, the 
sera were preabsorbed with noninfected Sf9 cell lysates. At 
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tured GAD6s on Western blots (Fig. 1 B). The results dem- 
onstrate that SMS autoantibodies  are directed at epitope(s) 
in the GAD6s molecule that are resistant to denaturation by 
SDS and are therefore likely to be continuous. Reactivity with 
these GAD6s-specific epitope(s)  qualitatively  distinguishes  Linear 
SMS autoantibodies from anti-GAD6s autoantibodies found  NH2-  terminal 
in IDDM and polyendocrine autoimmune disorder in the ab-  Pattern  epitope 
sence of SMS. 
SACS Autoantibodies  Recognize  Epitopes in the NH2-terminal 
Region of Denatured GADts.  Since GADts  differs most  IA  yes 
significantly from GAD67 in the first 95  amino acids, we 
speculated that  this  region might  harbor  GADts-specific  IB  yes 
SMS epitopes recognized by immunoblotting. To address this 
possibility, all sen were analyzed in parallel for reactivity with 
equal amounts of full-length rat GADts,  a 58-kD  tryptic 
fragment of rat  GAD6s  lacking  the first 69  or 70  amino 
acids, and a 55-kD deletion mutant lacking the first 101 amino  II  yes 
Table  3.  Distribution  of SMS-Patients  According  to 
Patterns of Epitope  Recognition  in  Denatured  GAD65 
Recognition of epitopes 
NH2-  Epitope 
terminal  in a  SMS- 
epitope  A101  patients 
predominant  mutant  no. 
yes  no  1,2,5,8,17, 
22,27,28,31 
yes  weak  7,10,11,13 
14,15,16,19 
21,23,24,25 
26,29,30,35 
no  strong  3,4,6,9,12, 
18,20,32,33, 
34 
Figure  1.  SMS sera recognize GADs but not GAD67 on Western blots 
and this reactivity distinguishes SMS from IDDM and polyendocrine an- 
toimmunity in the absence of SMS. (A) Lysates of Sf9 cells expressing 
human GAD67 (lanes I, 3, 5,  7, 9,  11) or GADts (lanes 2, 4, 6, 8,  10, 
12) produced from a baculovirus expression system were subjected to SDS- 
PAGE,  blotted to a PVDF membrane, and immunostained using the human 
sera indicated (PE, polyendocrine patient serum; NHS, normal human 
serum) at dilutions of 1:500 and the rabbit anti-GAD antiserum 1267 at 
dilution 1:100,000. (B) Lysates of SD cells expressing human GAD67 (hnes 
I, 3, 5) or GADts (lanes 2, 4, 6) immunostained  with SMS and IDDM 
sera preabsorbed to a Sfg-ceU  lysate  and diluted (SMS22, final dilution  1:388; 
IDDM1, final dilution 1:9) to obtain a titer of approximately 4 for GADes 
antibodies. Immunostaining  with the 1267 antiserum (dilution 1:20,000) 
is shown in lanes 1 and 2. 
acids of rat GAD6s (GADtsAI-101)  (Fig.  2 and Table 3). 
Among the SMS sera, two major patterns of reactivity were 
observed. The majority (25 of 35, or 71%) of SMS sera ex- 
hibited  pattern  I,  in  which  reactivity  with  fuU-length 
GAD65 was much stronger than with both the 58- and 55- 
kD fragments.  This  serological pattern suggests  that  the 
NHz-terminal 69 or 70 amino acids in rat GAD6s harbor a 
major linear epitope(s)  (Fig. 2,  lanes 4-15, and Table 3). 
Among the pattern I  sera, IgG in 9  (pattern  IA) reacted 
strongly with the fulblength GADts protein,  but did not 
recognize the 58- and 55-kD fragments, demonstrating that 
the recognition of denatured rat GAD6s was limited to the 
first 69 or 70 amino acids (Fig. 2,  lanes 4-9).  IgG in the 
remaining 16 SMS sera of the pattern I group (pattern  IB) 
reacted strongly with the full-length protein,  and were sig- 
nificantly less reactive with the 58- and 55-kD  fragments. 
This result  again  suggested  IgG that recognized  a major 
epitope in the first 69 or 70 amino acids but, in addition, 
minor epitope(s)  further downstream in  GADts  (Fig. 2, 
lanes 10-I5,  and Table 3). Thus for 71%  of the SMS sera 
(pattern IA and B), the major epitope recognized in dena- 
tured rat GADts resides in the first 69 or 70 amino acids. 
Pattern II reactivity, found in 10 of 35 SMS sera (29%, pat- 
tern II), was distinctly different in that reactivity with both 
the 58-kD tryptic fragment and the 55-kD deletion mutant 
was only minimally less than reactivity with the full-length 
protein (Fig. 2,  lanes 16-21, and Table 3).  Thus 29%  of 
the SMS patients had autoantibodies  that recognized an ad- 
ditional  major epitope(s) further downstream in the dena- 
tured GADbs molecule. In sum, residues 1-69 or 1-70 in rat 
GADbs contribute to a linear epitope(s) that is recognized 
by IgG in serum of all SMS patients,  and residues COOH 
terminal to amino acid 101  in rat GADts contribute to a 
second antigenic region that is recognized by IgG in only 
some SMS patients. 
600  NH2-terminal Linear GAD65 Epitope in Stiff-Man Syndrome Figure  2.  SMS sera show two patterns of reactivity 
with 58- and  55-kD COOH-terminal fragments  of 
rat GADds. Full-length GADds,  a 58-kD tryptic frag- 
ment of rat GAD65, and a 55-kD NH2-terminal  de- 
letion  mutant  of rat  GADds lacking  amino  acids 
1-101, were subjected to SDS-PAGE, blotted to PVDF 
membrane,  and immunostained  using the sera at the 
following dilutions:  SMS 1, 12, 18, 30 at 1:500, SMS 
2, 21 at 1:200, and IDDM and NHS at 1:500. SMS 
sera 1, 2, 21, and 30 (pattern  I) recognize a major epi- 
tope NH2-terminal  to  amino acid  69/70,  whereas 
SMS sera 12 and 18 (pattern II) also recognize a strong 
epitope COOH-terminal to amino acid 101. Among 
pattern  I sera, two subpatterns  are observed. In pat- 
tern IA, the sera only recognize the fill-length pro- 
tein.  In pattern I13, the sera recognize a weaker epi- 
tope COOH-terminal to amino acid  101. 
The Principal NHz-terminal Epitope Resides in the First Eight 
Amino Acids.  To further localize the SMS epitope(s) in the 
NH2-terminal  region,  we synthesized  ten peptides, each 20 
amino acids long,  spanning  residues  1-119  in  the  GAD6s 
molecule and overlapping each other by 9 amino acids. We 
tested the ability of the peptides to block the dot blot reac- 
tivity of SMS IgG with denatured GAD6s.  The first series 
of experiments  tested  three mixtures of peptides,  peptides 
1-3 (spanning residues 1--42), peptides 3-6 (residues 34-75), 
and peptides  7-10  (residues 67-119).  The mixture of pep- 
tides 1-3 completely blocked the reactivity of pattern IA sera, 
significantly blocked pattern 1t3 reactivity, and partially  blocked 
pattern II reactivity. These results are consistent with recog- 
nition of an epitope in the first 42 amino acids by both pat- 
tern I and pattern II sera. The mixture of peptides 4-6 did 
not affect the binding of SMS IgG to denatured GAD6s (not 
shown). The mixture of peptides 7-10 partially blocked the 
reactivities  of both pattern  I and pattern II sera. We next 
analyzed the ability of individual peptides  1, 2, 3,  7, 8,  9, 
and  10  to  block  the  binding  of SMS  IgG  to  denatured 
GAD6s.  These experiments  revealed that only peptide  1 of 
the 1-3 mixture inhibited the binding of SMS IgG to human 
GAD6s (see Fig.  3), suggesting that the first 11 residues of 
the NH2 terminus of GAD6s contribute  to an SMS epitope. 
This blocking was specific, because peptide  1 did not block 
Figure  3.  An NHz-terminal peptide of GAD,5 specifically blocks the 
binding of SMS sera. Human GADds purified from a baculovirns expres- 
sion system was spotted on a PVDF membrane and incubated with SMS 
sera (all at 1:500 dilution) or serum 1701 (raised to peptide  170, corre- 
sponding to 19 COOH-terminal amino acids in GAD, at a dilution of 
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1:200,000) that had been incubated  overnight with or without the indi- 
cated peptides  or human GADds. Peptide  1 completely  blocks  the reac- 
tivity of serum 1 (pattern IA), significantly inhibits the reactivity of serum 
11 (pattern  IB), partially  inhibits  the reactivity of serum  12 (pattern  II), 
but fails to inhibit serum 1701. Peptide 2 dues not inhibit binding of any 
of the sera and peptide 170 only inhibits binding of the serum 1701, which 
was raised against  it. Figure  4.  SMS sera  recognize  an epitope  lo- 
cated in the first eight NH2-terminal amino 
acids. Full-length rat GAD6s and short dele- 
tion mutants lacking 8 and 15 amino acids, 
respectively, were subjected to  SDS-PAGE, 
blotted to PVDF membranes, and immuno- 
stained with SMS sera at the following  dilu- 
tions: SMS 1, 7, 9, 12, 30 at 1:500 and SMS 
22 at 1:120. All the sera show identical signal 
or lack of signal with the 1-8 and 1-15 dele- 
tion mutants suggesting  that they  react equally 
well with both mutants and that the NHz- 
terminal epitope resides in  the  first eight 
residues, whereas residues 9-15 do not con- 
tribute to the epitope. 
the binding of rabbit  IgG raised against  either a COOH- 
terminal peptide (serum 1701, Fig. 3, panels 25/26) or a pep- 
tide encompassing  residues 83-93 in the NH2-terminal re- 
gion (serum 2001, not shown). Each of these antisera were 
blocked by the peptide against which they were raised (Fig. 
3, panels 31/32 and results not shown). Only peptide 7, in 
the mixture 7-10, caused any block of the reactivity of SMS 
sera.  However, blocking by peptide  7 was not  specific be- 
cause it also inhibited the reactivity of several rabbit antisera 
raised against  irrelevant  peptides  (not  shown).  The reason 
for nonspecific inhibition  by peptide  7  of IgG binding  to 
GAD65 on dot blots is unclear.  This activity was not found 
with peptides 6 and 8, which together  account for all but 
two of the amino acids in peptide 7. Thus, among the NH2- 
terminal  peptides spanning  the first  119 amino  adds,  only 
peptide 1 specifically blocked the pattern I reactivity of SMS 
IgGs and partly inhibited  the reactivity of pattern  II SMS 
IgGs.  This  result  is  consistent  with  a  major  linear  NH2- 
terminal SMS epitope residing in the first 11 amino acids of 
GAD65. 
To further analyze the reactivity  of SMS IgG with the 
NH2-terminal  region  of GAD6s,  deletion mutants  lacking 
the first  8  and  15 amino  acids  of rat  GAD65,  respectively, 
were analyzed by immunoblotting for interaction with SMS 
IgG (Fig. 4). These experiments demonstrated that pattern 
I  sera reacted either very weakly (pattern  IB) or not  at all 
(pattern  IA) with both  the A1-8 and A1-15 deletion mu- 
tants (Fig.  4, lanes 4-15). In contrast,  pattern II sera recog- 
nized both deletion mutants (Fig. 4, lanes 16-21). All of the 
SMS sera either failed to react with both of the short dele- 
tion mutants or showed equal reactivity to both of them (Fig. 
4), indicating  that  the NH2-terminal  linear  epitope recog- 
nized by SMS sera resides in amino acids 1-8 and that amino 
acids 9-15 do not contribute to this or other SMS epitopes. 
The results of the peptide blocking experiments and anal- 
yses of deletion mutants  localize the NH2-terminal  epitope 
recognized by SMS sera to  the first 8  amino  acids. 
HLA-DRBl*0301, DQB1 "0201 Is the Predominant  Haplo- 
type among Patients of Pattern I Seropositivity.  Many autoim- 
mune diseases, including IDDM, are strongly associated with 
certain MHC class II haplotypes. Thus >/95 % of IDDM pa- 
tients  carry  the  HLA-DRBI*0301,  DQBI*0201  (D1L3, 
DQw2) and/or DRBI*0401, DQBI*0302 (DR4, DQ8) sus- 
ceptibility haplotypes (35). To assess whether SMS and IDDM 
have similar HLA-association, we obtained lymphocytes from 
12 of the SMS patients,  9 with  serological pattern  I  and 3 
with serological pattern II. (Table 4, and Lennon, V., S. Baek- 
keskov,  T. Bugawan, and H. Erlich,  manuscript in prepara- 
tion). 9 of the 12 SMS patients carried the IDDM associated 
allele  DQw2 (DQBI*0201),  8 on the DIL3 (DRBI*0301) 
and one on the DR7 (DRBI*0701) haplotype. Amongst the 
DQw2 positive patients,  8 (4 of whom were homozygous) 
had  serological pattern  I  reactivity  and one had pattern  II 
reactivity. The only non-DQ2 positive patient with pattern 
I was positive for the IDDM associated haplotype DR4, DQ8 
(Table 4).  Thus all nine patients  with serological pattern  I 
but only one of the three patients  of pattern  II carried an 
IDDM associated haplotype (Table  4).  One of the pattern 
II  patients  carried  the  DRBl*1501,  DQBI*0603  (DR2, 
DQw6) haplotype, which is protective for IDDM (36). The 
DR3,  DQw2  IDDM-associated  haplotype  is  particularly 
abundant, whereas the DR4, DQw8 IDDM-associated haplo- 
type is rare in the pattern I SMS patients (Lennon V., S. Baek- 
keskov,  T.  Bugawan,  and  H.  Erlich,  manuscript  in  prepa- 
ration). 
Table  4.  DR and DQ Haploty~s of SMS Patients 
SMS 
patient 
no.  DRBI  DQB1 
GAD6sAb 
Western blot 
pattern 
1  0701 
2  0301 
3  1601 
4  1501 
6  0301 
7  0301 
8  0404 
11  0301 
14  0301 
15  0301 
19  0301 
30  0301 
1302  0201 
0301  0201 
1401  0502 
1301  0603 
0901  0201 
0401  0201 
1103  0302 
0301  0201 
0401  0201 
0400  0201 
0301  0201 
0301  0201 
0604 
0201 
0503 
0602/O3 
0303 
0301/02 
0301 
0201 
0302 
0301 
0201 
0201 
I 
I 
II 
II 
II 
I 
I 
I 
I 
I 
I 
I 
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Figure 5.  Schematic  drawing of the GAD65 molecule  showing  loca- 
tion of humeral  epitope  areas, membrane  anchoring  regions, and proteo- 
lytic hot spot. 
Discussion 
Linear Epitopes in GAD6s.  We  have identified  a linear 
NH2-terminal  epitope  in  the  autoantigen  glutamic  acid 
decarboxylase, GAD6s, that is specifically  recognized by au- 
toantibodies  in serum of patients with SMS (Fig. 5). This 
epitope is not recognized by anti-GAD6s autoantibodies that 
are associated with 3  ceU destruction and development of 
insulin-dependent  diabetes in the absence of SMS (Fig. 5). 
Hence specifidty for the linear NH2-terminal epitope distin- 
gnishes IgG autoantibodies  of SMS patients from those of 
IDDM patients. Antibodies of this specificity may be impor- 
tant for the prediction and diagnosis of SMS. 
A recent Western blot study of SMS antibody reactivity 
with GAD6s used bacterially expressed recombinant frag- 
ments of rat GAD6s coupled to a maltose binding protein 
(24). A fragment containing residues 475-585 of rat GAD6s 
was recognized much more strongly than full-length GAD6s, 
but the reactivity was abolished by deleting either residues 
475-483  or residues 582-585.  Based on these results,  the 
authors  concluded that the major SMS epitope recognized 
on Western blots is not linear but rather conformational and 
generated by refolding of the denatured amino acid 475-585 
fragment on nitrocellulose.  To explain why a partial  frag- 
ment  was  more reactive  than  wild-type rat  GADes,  the 
authors suggested that the conformational epitope in residues 
475-585 is partly cryptic in the native molecule (24). Con- 
sistent with our results, Butler et al. (24), also reported that 
SMS antibodies recognize rat GAD6s fragments containing 
amino acids 1-95  or 1-195 on Western blots,  albeit more 
weakly than the 475-585  fragment. 
The pattern  II  specificity defined in  our study clearly 
identifies a major epitope(s) COOH-terminal to residue 101 
in denatured rat GAD6s on Western blots, which may rep- 
resent the nonlinear epitope described by Butler et al. (24). 
However pattern II reactivity only accounted for 29% of the 
SMS sera analyzed in our study. The remaining 71% of SMS 
sera had a reactivity that was consistent with recognition of 
a dominant NH2-terminal  linear epitope  but not a major 
epitope  further downstream in  denatured rat  GAD65 on 
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Western blots. The difference between our results and those 
of  Butler et al. (24) is not readily explained. Several  possibili- 
ties can be suggested. First,  we have analyzed all SMS pa- 
tients at the Mayo Clinic and UCSF over the last 5 yr. The 
study by Butler et al. (24) used sera from 30 patients which 
were selected from a cohort of 72 SMS patients by unknown 
criteria; the selection procedure may have favored pattern II 
sera. Second, their immunoblotting protocol may enhance 
renaturation of the amino acid 475-585 epitope on Western 
blots. A third possibility is that the coupling of the 475-585 
fragment to a maltose binding protein enhances its refolding 
on nitrocellulose. 
In addition to linear epitopes associated with SMS and 
IDDM respectively (Fig. 5), Ujihara et al. (36) have identified 
a third linear epitope in residues 421-442 in the GAD6s pro- 
tein. This epitope is recognized by IgG in a rare group of 
IDDM relatives that develop high titers of GAD6s autoan- 
tibodies yet carry the HLA-DRBl*1501, DQBI*0603 (DR2, 
DQw6) haplotype which is protective for diabetes. Interest- 
ingly, one of the three SMS patients of pattern II who was 
HLA-haplotyped carried this haplotype. We speculate that 
additional pattern II patients,  amongst whom IDDM was 
rare (20%) compared with pattern I patients  (44%), may 
carry alleles that are protective for IDDM and that pattern 
II may in some cases include recognition of the epitope de- 
scribed by Ujihara et al. (36). In comparison,  none of the 
9 pattern I patients who were HLA-haplotyped were DR2, 
DQw6 positive. Rather they all carried one or two IDDM 
susceptibility alleles and the DR3, DQw2 allele was particu- 
larly abundant (7/9). 
The NH2-terminal  linear epitope identified in our study 
is identical in rat and human GAD6s, which overall share 
I>95%  sequence  homology (17). Although  it  has  been 
reported that SMS sera recognize  rat and human GAD6s 
equally well (24), our preliminary results suggest  that the 
downstream epitope(s) may differ between the rat and human 
autoantigen.  Thus a 58-kD tryptic fragment of the human 
protein is recognized more strongly on Western blots by some 
pattern IB and pattern II sera than its rat counterpart. Gener- 
ation of mutants of the human protein and expression in cel- 
lular expression systems will be important for characterizing 
the SMS epitope(s) contained in the 58-kD tryptic fragment. 
SMS Sera Have an Increased GAD Epitope Recognition Com- 
pared with IDDM Sera.  Anti-GAD6s autoantibodies  differ 
significantly in SMS and IDDM patients with regard to titers 
measured by immunoprecipitation.  Titers of autoantibodies 
associated with SMS are orders of magnitude higher than 
in IDDM sera. Thus SMS is characterized by a much stronger 
humoral autoimmune response to GAD6s than is IDDM. 
Is the strong antibody response to GAD6s in SMS a re- 
sult of (a) an increased humoral epitope repertoire in this dis- 
ease compared with IDDM; (b) an enhanced immune response 
to certain epitopes, or (c) a combination of both? Since no 
monoclonal autoantibodies  are yet available from SMS pa- 
tients, this question is difficult to address directly. However, 
considerable indirect evidence suggests that the humoral re- 
sponse in SMS sera is more broad than in IDDM. By immu- 
noprecipitation  assay, both SMS and IDDM sera recognize an NHz-terminal deletion mutant of GAD6s lacking the first 
244 amino acids (22, and Shi, Y., and S. Baekkeskov, unpub- 
lished results). This suggests that IgGs in SMS and IDDM 
sera recognize conformational epitopes in the COOH-terminal 
half  of  the  molecule.  In  addition,  SMS  autoantibodies 
specifically recognize the linear NHz-terminal epitope iden- 
tified in this study. Finally,  the incidence of GAD67 autoan- 
tibodies in IDDM patients is only 10-20%  (8, 9), whereas 
sera  of SMS  patients  generally immunoprecipitate native 
GAD67 (24, 37) albeit less efficiently than GAD6s (24).  On 
Western blots, SMS sera react specifically with GAD6s and 
do not recognize GAD67. In sum, the humoral autoimmune 
response in SMS seems to include conformational epitopes 
(detected by immunoprecipitation) as well as linear epitope(s) 
(recognized in Western blots)  that  are not recognized by 
IDDM sera. It is likely that the stronger antibody responses 
associated with SMS reflect both a broader repertoire of epi- 
topes than is characteristic of IDDM as well as higher affinity 
for shared epitopes. 
The Linear NH2-terminal Epitope Is Upstream  from the Mem- 
brane Anchoring Domain and a Proteolytic Hot Spot.  We have 
localized the vesicle targeting and membrane anchoring se- 
quences in GAD6s to the second exon of the molecule (5) 
that spans amino acids 25-41 (2).  GAD6s has a proteolytic 
hot spot around residues 69-75 encoded by the third exon 
(Fig. 5). GAD6s can be released spontaneously from islet cell 
membranes as a 57-58 kD hydrophilic soluble fragment in 
a time-dependent manner (4). The kinetics of this reaction 
are consistent with an enzymatic cleavage in islet cells (4). 
We speculate that this enzymatic activity may also reside in 
neurons  and perhaps  result  in  enhanced exposure of the 
NH2-terminal SMS epitope in a 7-8-kD fragment that re- 
mains membrane associated  after cleavage. 
All SMS Patients Are Positive  for Antibodies to GAD6s.  In 
a study of 32 SMS patients from seven different countries, 
which only found GAD autoantibodies in 20 patients (63%), 
it was suggested that SMS patients can be divided into two 
groups based on whether they have GAD autoantibodies or 
not (13). Most of the patients analyzed in our study were 
diagnosed at the Mayo Clinic in Rochester, where the dis- 
ease  was  discovered and  first  described by  Moersch  and 
Woltman (38). Two patients were diagnosed at UCSF using 
clinical diagnostic criteria similar to those of the Mayo Clinic 
(14). All 35 patients were positive for GAD65 autoantibodies 
both in immunoprecipitation and Western blot assays. Our 
results suggest that a diagnosis of SMS using standardized 
clinical criteria identifies a uniform group of patients with 
strong humoral autoimmunity to GAD6s.  A SMS-like dis- 
order associated with breast carcinoma was, however, recently 
described in four patients who were seronegative for anti- 
GAD6s antibodies but positive for autoantibodies to a second 
synaptic vesicle protein, amphiphysin (39). Thus anti-GAD6s 
autoantibodies may only be a universal characteristic of SMS 
in the absence of a paraneoplasia. 
Role of B  Cells and GAD6a Autoantibodies in IDDM and 
SMS.  In spontaneous rodent modds of IDDM, disease can 
be transferred by T  cells but not B cells (10) and immuno- 
electronmicroscopic studies suggest that fl cell destruction 
is mediated by cytotoxic T  cells (40).  The primary Th re- 
sponses to GAD6s in the nonobese diabetic mouse are of the 
Thl subset (12), which is consistent with induction of cyto- 
toxic T  cell responses.  Although autoantibodies to GAD6s 
have not been implicated as effectors of fl cell destruction, 
it is conceivable that B cells, expressing GAD6s-specific IgG 
on the surface,  play an important role in antigen presenta- 
tion in IDDM.  Activated B cells are particularly efficient 
presenters of low abundance antigens by virtue of antigen 
capture by their surface immunoglobulins (41) and may well 
be the principal antigen presenting cells that can maintain 
chronic autoimmunity to a rare antigen like GAD6s over the 
several years of progressive fl cell destruction. The antibody 
binding to an antigen can influence its processing in endosomal 
compartments, and consequently the presentation of epitopes 
to T  cells. Thus, antibody binding can suppress  some epi- 
topes while boosting others (42).  The identification of hu- 
moral autoimmune epitopes in the GAD6s molecule which 
are associated with either IDDM susceptibility (22) or pro- 
tection (36)  may provide an example of how specificity of 
autoantibodies can influence autoimmune T  cell responses 
resulting in either fl cell destruction and disease, or absence 
of disease. 
Do autoantibodies to GAD65 have a pathogenic role in 
SMS?  Although the strong humoral autoimmune GAD6s 
responses in SMS may suggest a more direct role of autoanti- 
bodies in impairment of GABA-ergic neurons than in de- 
struction of fl cells, the pathogenicity of SMS antibodies re- 
mains to be shown. It is noteworthy that in the absence of 
MHC class I expression (18) autoimmune effector mecha- 
nisms directed at neurons would be limited to antibody re- 
sponses.  Furthermore, an involvement of a Th2 subset of 
CD4 § cells and strong antibody responses to GAD6s in the 
pathogenicity of SMS, in contrast to a requirement for a Thl 
subset and cytotoxic T cell responses for fl cell destruction, 
is consistent with the dichotomy of the two diseases. Thus 
SMS without IDDM would ensue in the absence of Thl helper 
cell and cytotoxic T  cell responses to GAD6s. 
An autoantibody-mediated impairment of GABA-ergic 
neurons would, however, require antigen exposure at the cell 
surface. Although there is some evidence to suggest that GAD 
can appear on the surface of neurons (43),  the mechanisms 
of such exposure are unclear. GAD6s is believed to anchor 
at the cytosolic face of synaptic vesicle membranes and sur- 
face expression during exocytosis of GABA would require 
a membrane translocation step.  The identification of am- 
phiphysin as a target of autoantibodies in a paraneoplastic 
SMS-like syndrome (39) does suggest that a localization of 
a protein to the cytosolic face of synaptic vesicle membranes 
can predispose it for autoantigenicity and that such proteins 
may reach the cell surface by an as yet unknown mechanism. 
Alternatively, SMS autoantibodies may not be involved in 
pathogenicity but rather be only a marker of disease. 
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